

Phase II, multicentre, double blind, placebo controlled, parallel group, dose ranging study of ATL-962 (cetilistat) to assess weight loss, safety and tolerability in obese patients with Type II diabetes being treated with metformin, in comparison with orlistat

Submission date 05/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 16/09/2005	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 14/10/2009	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Peter Kopelman

Contact details
Barts and The London
Queen Mary's School of Medicine & Dentistry
30-32 Newark Street
London
United Kingdom
E1 2AA

Additional identifiers

Protocol serial number
ATL-962/175/CL, orlistat

Study information

Scientific Title

Study objectives

Does ATL-962 induce weight loss in diabetic patients and is its safety and tolerability profile superior to that of orlistat in such patients?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised three arm placebo controlled parallel group trial

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Obesity in patients with Type II diabetes

Interventions

ATL-962 (40 mg, 80 mg, or 120 mg), or placebo, or orlistat (120 mg) three times a day for 12 weeks

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

ATL-962 (cetilistat), orlistat, metformin

Primary outcome(s)

Absolute weight loss compared to baseline

Key secondary outcome(s)

Proportion of patients achieving 5% or 10% weight loss; changes in waist circumference; changes in lipid profiles; changes in markers of diabetes; incidence of GI adverse events; changes in other safety parameters

Completion date

30/06/2005

Eligibility

Key inclusion criteria

1. Type II diabetic patients
2. Aged 18-65
3. Body Mass Index (BMI) between 28 kg/m² and 45 kg/m²
4. Glycosylated haemoglobin (HbA1c) value between 6% and 10%
5. Being treated with a stable dose of metformin

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Upper age limit

65 Years

Sex

Not Specified

Key exclusion criteria

1. Significant weight loss in the previous 3 months
2. Weight gain during the run-in period
3. Other serious systemic disease, except for controlled hypertension, mild asthma, and primary hypothyroidism
4. History of GI disorders
5. Previous surgery for weight loss

Date of first enrolment

01/12/2004

Date of final enrolment

30/06/2005

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Barts and The London
London
United Kingdom
E1 2AA

Sponsor information

Organisation
Alizyme (UK)

Funder(s)

Funder type
Industry

Funder Name
Alizyme (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2010		Yes	No